These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8852543)

  • 21. Effect of lacidipine, a dihydropyridine calcium antagonist on renal function of hypertensive patients with renal insufficiency.
    Bailey RR; Shand BI; Smith AH; Robson RA; Lynn KL
    Clin Nephrol; 1997 Oct; 48(4):224-9. PubMed ID: 9352156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcium antagonists in heart failure.
    Klugmann S; Salvi A; Camerini F
    Herz; 1983 Apr; 8(2):88-92. PubMed ID: 6852766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. French large-scale study evaluating the tolerability and efficacy of lacidipine.
    Tcherdakoff P
    J Cardiovasc Pharmacol; 1995; 25 Suppl 3():S27-32. PubMed ID: 8852542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enalapril for severe congestive heart failure. A double-blind study.
    Jennings G; Kiat H; Nelson L; Kelly MJ; Kalff V; Johns J
    Med J Aust; 1984 Nov; 141(11):723-6. PubMed ID: 6094995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety profile of lacidipine: a review of clinical data.
    Endersby CA; Brown EG; Perelman MS
    J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S45-7. PubMed ID: 1726006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcium channel antagonists. What do the second-generation agents have to offer?
    Salerno SM; Zugibe FT
    Postgrad Med; 1994 Jan; 95(1):181-90. PubMed ID: 8278298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of felodipine and enalapril in patients with congestive heart failure.
    de Vries RJ; Queré M; Lok DJ; Sijbring P; Bucx JJ; van Veldhuisen DJ; Dunselman PH
    Am J Cardiol; 1995 Dec; 76(17):1253-8. PubMed ID: 7503006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nicardipine in heart failure: distinguishing its acute beneficial from its chronic effects.
    Sy J; Vitarelli A; Gheorghiade M
    Minerva Cardioangiol; 1993 Nov; 41(11):535-41. PubMed ID: 8127455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators.
    Boden WE; Ziesche S; Carson PE; Conrad CH; Syat D; Cohn JN
    Am J Cardiol; 1996 May; 77(12):1078-82. PubMed ID: 8644661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension.
    Fogari R; Zoppi A; Corradi L; Preti P; Malalamani GD; Mugellini A
    J Hypertens; 2000 Dec; 18(12):1871-5. PubMed ID: 11132613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurohumoral profile in congestive heart failure: response to beta-blockade.
    Binkley PF; Lewe R; Lima J; Unverferth DV; Leier CV
    J Lab Clin Med; 1988 Apr; 111(4):393-8. PubMed ID: 2895155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolving role of calcium channel blockers in heart failure.
    Pieper JA
    Pharmacotherapy; 1996; 16(2 Pt 2):43S-49S. PubMed ID: 8668605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcium-channel blockade in the management of severe chronic congestive heart failure: a bridge too far.
    Packer M; Kessler PD; Lee WH
    Circulation; 1987 Jun; 75(6 Pt 2):V56-64. PubMed ID: 3552317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Defining the role of calcium channel antagonists in heart failure due to systolic dysfunction.
    Mahé I; Chassany O; Grenard AS; Caulin C; Bergmann JF
    Am J Cardiovasc Drugs; 2003; 3(1):33-41. PubMed ID: 14727944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cardiac and vascular effects of lacidipine.
    Agabiti-Rosei E
    J Cardiovasc Pharmacol; 1995; 25 Suppl 3():S1-5. PubMed ID: 8852537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of piretanide, a potassium stable diuretic, on serum electrolytes in patients with congestive heart failure.
    Verho M; Bückert C; Freude J; Jaeger S; Pahnke K
    Pharmatherapeutica; 1985; 4(5):288-95. PubMed ID: 3906674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Influence of the neurohumoral system on left ventricular performance in chronic congestive heart failure].
    Mattioli AV; Modena MG; Masciocco L; Fantini G; Mattioli G
    Cardiologia; 1992 Feb; 37(2):129-34. PubMed ID: 1600530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative study of lacidipine and nifedipine SR in the treatment of hypertension: an Italian multicenter study. The Northern Italian Study Group of Lacidipine in Hypertension.
    Leonetti G
    J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S31-4. PubMed ID: 1726003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines.
    de Vries RJ; van Veldhuisen DJ; Dunselman PH
    Am Heart J; 2000 Feb; 139(2 Pt 1):185-94. PubMed ID: 10650289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Body fluid withdrawal with isolated ultrafiltration effects persistent improvement of functional capacity in patients with chronic congestive heart failure. Furosemide does not produce the same result].
    Marenzi G; Guazzi M; Lauri G; Perego GB; Sganzerla P; Agostoni P
    Cardiologia; 1994 Nov; 39(11):763-72. PubMed ID: 7736475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.